Veliparib
- Generic Name
- Veliparib
- Drug Type
- Small Molecule
- Chemical Formula
- C13H16N4O
- CAS Number
- 912444-00-9
- Unique Ingredient Identifier
- 01O4K0631N
- Indication
与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors
- Conditions
- Solid Neoplasm
- Interventions
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT01017640
- Locations
- 🇺🇸
Georgetown Cancer Treatment Center, Georgetown, Kentucky, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
- Conditions
- Recurrent Primary Peritoneal CarcinomaMetastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaUnresectable Solid NeoplasmRecurrent Ovarian Carcinoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacogenomic StudyOther: Pharmacological Study
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT01012817
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
- Conditions
- Breast CancerMetastatic Breast CancerBRCA1 Gene Mutationbrca2 Gene Mutation
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Steven J Isakoff, MD, PhD
- Target Recruit Count
- 63
- Registration Number
- NCT01009788
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
- Conditions
- AstrocytomaPNETMedulloblastomaEpendymomaPontine Glioma
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT00994071
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Fallopian Tube CarcinomaFallopian Tube CarcinosarcomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Transitional Cell CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Serous AdenocarcinomaOvarian Transitional Cell CarcinomaPrimary Peritoneal Serous AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma
- Interventions
- Biological: BevacizumabOther: Laboratory Biomarker Analysis
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 431
- Registration Number
- NCT00989651
- Locations
- 🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
- Conditions
- Childhood CraniopharyngiomaChildhood Grade I MeningiomaChildhood Mixed GliomaChildhood Supratentorial EpendymomaRecurrent Childhood Brain TumorRecurrent Childhood Spinal Cord NeoplasmRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorChildhood Grade II MeningiomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral Astrocytoma
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00946335
- Locations
- 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
- Conditions
- BRCA1 Mutation CarrierBreast CarcinomaEstrogen Receptor NegativeHER2/Neu NegativeHereditary Breast and Ovarian Cancer SyndromeBasal-Like Breast CarcinomaProgesterone Receptor NegativeSolid NeoplasmBRCA2 Mutation CarrierOvarian Carcinoma
- Interventions
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 98
- Registration Number
- NCT00892736
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope South Pasadena, South Pasadena, California, United States
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
- Conditions
- Metastatic MelanomaSkin CancerMelanoma
- Interventions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 346
- Registration Number
- NCT00804908
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Genetic: DNA methylation analysisGenetic: gene expression analysisGenetic: mutation analysisGenetic: proteomic profilingOther: high performance liquid chromatographyOther: immunoenzyme techniqueOther: laboratory biomarker analysisOther: mass spectrometryOther: pharmacogenomic studiesOther: pharmacological studyProcedure: adjuvant therapyRadiation: radiation therapy
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2018-06-27
- Target Recruit Count
- 24
- Registration Number
- NCT00770471
- Locations
- 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
- Conditions
- Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 81
- Registration Number
- NCT00740805
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.